Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.14% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NetEase
NTES
$82.9B
| $820M | 1.05% |
13,630,000
+2,281,500
| +20% | +$131M |
|
2
Johnson & Johnson
JNJ
$603B
| $811M | 1.04% |
6,132,200
-970,500
| -14% | -$124M |
|
|
3
Bristol-Myers Squibb
BMY
$124B
| $752M | 0.96% |
13,488,200
+7,020,200
| +109% | +$382M |
|
4
Gilead Sciences
GILD
$162B
| $737M | 0.94% |
10,407,848
+2,700,600
| +35% | +$180M |
|
|
5
Colgate-Palmolive
CL
$72.4B
| $723M | 0.92% |
9,753,400
+2,903,800
| +42% | +$216M |
|
6
NVIDIA
NVDA
$5.02T
| $688M | 0.88% |
190,351,720
+30,728,000
| +19% | +$97.6M |
|
7
Humana
HUM
$48.5B
| $657M | 0.84% |
2,731,100
+39,400
| +1% | +$8.92M |
|
8
PepsiCo
PEP
$184B
| $652M | 0.83% |
5,642,700
+1,298,900
| +30% | +$149M |
|
9
Domino's
DPZ
$10.9B
| $647M | 0.83% |
3,060,900
+930,200
| +44% | +$184M |
|
10
Amgen
AMGN
$198B
| $586M | 0.75% |
3,400,145
+986,700
| +41% | +$160M |
|
|
NVO
11
Novo Nordisk
NVO
$218B
| $580M | 0.74% |
27,068,600
-5,749,800
| -18% | -$116M |
|
12
Mastercard
MA
$476B
| $535M | 0.68% |
4,403,900
-848,800
| -16% | -$101M |
|
13
Crown Castle
CCI
$33.3B
| $488M | 0.62% |
4,875,503
+876,900
| +22% | +$86.2M |
|
14
VeriSign
VRSN
$24.2B
| $469M | 0.6% |
5,045,476
+941,100
| +23% | +$85M |
|
|
15
Eli Lilly
LLY
$1.05T
| $469M | 0.6% |
5,694,905
+2,714,505
| +91% | +$221M |
|
16
IBM
IBM
$198B
| $418M | 0.53% |
2,845,434
+728,644
| +34% | +$110M |
|
|
BCR
17
DELISTED
CR Bard Inc.
BCR
| $410M | 0.52% |
1,295,600
+338,900
| +35% | +$101M |
|
18
GSK
GSK
$102B
| $403M | 0.51% |
7,470,400
+3,948,720
| +112% | +$211M |
|
19
Cboe Global Markets
CBOE
$28.7B
| $399M | 0.51% |
4,369,996
-97,304
| -2% | -$8.31M |
|
20
Walmart Inc
WMT
$878B
| $383M | 0.49% |
15,189,300
+59,100
| +0.4% | +$1.5M |
|
21
Philip Morris
PM
$293B
| $360M | 0.46% |
3,066,800
+1,139,900
| +59% | +$132M |
|
22
Chubb
CB
$138B
| $350M | 0.45% |
2,404,461
+449,500
| +23% | +$63.3M |
|
23
American Electric Power
AEP
$71B
| $332M | 0.42% |
4,778,600
+394,800
| +9% | +$27.4M |
|
24
Northrop Grumman
NOC
$72.8B
| $320M | 0.41% |
1,245,400
+256,200
| +26% | +$64.1M |
|
|
TWX
25
DELISTED
Time Warner Inc
TWX
| $313M | 0.4% |
3,117,334
+439,000
| +16% | +$43.5M |
|
Similar funds
Renaissance Technologies's Q2 2017 Portfolio in Review
As of Q2 2017, Renaissance Technologies held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Renaissance Technologies deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Renaissance Technologies's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Renaissance Technologies's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Renaissance Technologies fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Renaissance Technologies's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Renaissance Technologies opened 398 new positions and closed 418 in Q2 2017.
- Renaissance Technologies's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.